Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rilparencel
- Development stage
- Phase 3
- Lead developer
- ProKidney
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intra-renal
01
Overview
Rilparencel (also known as REACT) is a first-in-class, autologous cellular therapy developed by ProKidney for the treatment of advanced chronic kidney disease (CKD), particularly in patients with diabetic nephropathy. The therapy is produced by isolating a patient's own kidney cells from a biopsy, expanding specific renal epithelial cells in a laboratory, and formulating them into a personalized product for re-injection. Administered via a percutaneous intra-renal injection, rilparencel is designed to stabilize or improve kidney function by reducing inflammation, fibrosis, and the progressive scarring that leads to kidney failure. It has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and is currently being evaluated in Phase 3 clinical trials.
- Brand names
- REACT
- Other names
- Renal Autologous Cell Therapy
Beyond the preview
Go deeper on rilparencel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rilparencel.